P-Glycoprotein Inhibitors

BCL-2 Inhibitor

Leukemia, Lymphoid

<section class="Section" data-sectioncode="34089-3"><a name="section-10"></a><h1>11 DESCRIPTION</h1>Venetoclax is a BCL-2 inhibitor. It is a light yellow to dark yellow solid with the empirical formula C45H50ClN7O7S and a molecular weight of 868.44. Venetoclax is described chemically as 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide) and has the following chemical structure: <img alt="the following chemical structure for Venetoclax is a BCL-2 inhibitor. It is a light yellow to dark yellow solid with the empirical formula C45H50ClN7O7S and a molecular weight of 868.44. Venetoclax is described chemically as 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide)." src="venetoclax-spl-01.jpg"/>Venetoclax has very low aqueous solubility. VENCLEXTA tablets for oral use are supplied as pale yellow or beige tablets that contain 10, 50, or 100 mg venetoclax as the active ingredient. Each tablet also contains the following inactive ingredients: copovidone, colloidal silicon dioxide, polysorbate 80, sodium stearyl fumarate, and calcium phosphate dibasic. In addition, the 10 mg and 100 mg coated tablets include the following: iron oxide yellow, polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide. The 50 mg coated tablets also include the following: iron oxide yellow, iron oxide red, iron oxide black, polyvinyl alcohol, talc, polyethylene glycol and titanium dioxide. Each tablet is debossed with “V” on one side and “10”, “50” or “100” corresponding to the tablet strength on the other side. </section>

Venclexta

venetoclax

venetoclax 100 MG Oral Tablet

venetoclax 100 MG Oral Tablet [Venclexta]

venetoclax 10 MG Oral Tablet

venetoclax 50 MG Oral Tablet

venetoclax 10 MG Oral Tablet [Venclexta]

venetoclax 50 MG Oral Tablet [Venclexta]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

How to Order Venclexta 

Billing & Coding Guide: Small Lymphocytic Lymphoma (SML)

Billing & Coding Guide: Chronic Lymphocytic Leukemia (CLL)

Billing & Coding Guide: Acute Myeloid Leukemia (AML)

Venclexta Prescriber Service Form 

Venclexta Patient Consent Form 

Venclexta Patient Consent Form - Spanish

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Enroll in Patient Savings Program 

Genentech Patient Foundation Application Form (1/2)

Genentech Patient Foundation Application Form (2/2) - Patient Consent Form 

Venclexta Sure Start Program (Bridge Program)

Other HCP Resources: Expert Videos 

Other HCP Resources 

Patient Brochure: AML

How Venclexta is Supplied 

About Venclexta: AML

Taking Venclexta: AML

Instructions For Use: AML

Side Effects: AML

Patient Resources: AML

Patient Brochure: CLL/SLL

Patient Brochure: CLL/SLL - Spanish

About Venclexta: Previously Untreated CLL/SLL

Taking Ventoclax: Previously Untreated CLL/SLL

Instructions For Use: Previously Untreated CLL/SLL

Side Effects: Previously Untreated CLL/SLL

Patient Stories: Previously Untreated CLL/SLL

About Venclexta: Previously Treated CLL/SLL

Patient Stories: Previously Treated CLL/SLL

Taking Venclexta: Previously Treated CLL/SLL

Instructions For Use: Previously Treated CLL/SLL

Side Effects: Previously Treated CLL/SLL

Patient Resources: Financial Support 

Patient Resources: CLL/SLL

CLL Doctor Discussion Guide 

Dosing Tracker Calendar 

Venclexta Patient Support Programs Brochure 